Rapidly disintegrating solid oral dosage forms containing dasatinib

Inventors

Andersson, Per • Meijer, Thomas • Söderberg, Victor

Assignees

Xspray Pharma AB

Interested in licensing this patent?

MTEC can help explore whether this patent might be available for licensing for your application.

Publication Number

US-10874614-B1

Patent

Publication Date

2020-12-29

Expiration Date


Abstract

The instant application relates to the field of pharmaceutical compositions comprising dasatinb. Furthermore, the instant application relates to a method of treating proliferative disorders in a patient in need thereof, comprising administering a therapeutically effective amount of said compositions.

Core Innovation

The invention provides a tablet for oral administration comprising dasatinib (S)-1,2-propanediol solvate, at least one pharmaceutically acceptable excipient, and a coating layer. The tablet is defined by an in vitro release performance in a USP Type 2 apparatus with 500 mL of 0.01 M hydrochloric acid at about 37°C and about 75 RPM. The tablet releases at least 80% of the dasatinib within 20 minutes and is provided with an amount equivalent to 50 mg dasatinib.

The disclosure situates the formulation within rapid oral dasatinib solid dosage forms intended to address previously observed variability problems associated with dasatinib and to support regulatory bioequivalence. The document describes bioequivalence and reference scaled average bioequivalence considerations, including use of 90% confidence interval acceptance criteria for AUC and Cmax. The tablet is characterized for oral administration relative to a reference dasatinib monohydrate listed drug using specific acceptance ranges for the ratios of mean AUC(0-∞) and mean Cmax.

The tablet is further supported by dissolution and bioavailability characterization within the described testing context, including dissolution testing results and an example pharmacokinetic study. The document indicates that the tablet provides unexpectedly dramatic dissolution under the specified USP Type 2 conditions and demonstrates comparable bioavailability versus Sprycel® (dasatinib monohydrate). The example characterization includes 90% confidence interval results for AUCinf (fasted) and Cmax (fasted), reported as meeting within/near acceptance.

Claims Coverage

The claims include one independent claim and dependent claims that refine composition, dissolution performance, and regulatory bioequivalence characterization versus a reference listed drug. The independent claim identifies the core tablet structure and a defined dissolution release threshold under USP Type 2 conditions, while dependent claims add composition and acceptance-range criteria.

Rapid-release dasatinib (S)-1,2-propanediol solvate tablet with defined USP Type 2 release

A tablet for oral administration comprising dasatinib (S)-1,2-propanediol solvate, at least one pharmaceutically acceptable excipient, and a coating layer, wherein the tablet releases at least 80% of the dasatinib within 20 minutes when tested in a USP Type 2 apparatus in 500 mL of 0.01 M hydrochloric acid at about 37°C and about 75 RPM, and wherein the amount of dasatinib is equivalent to 50 mg dasatinib.

Coating-layer excipient options

The tablet wherein the coating layer comprises glyceryl monostearate, hypromellose, poly(vinyl alcohol), polyethylene glycol, polysorbate 80, sodium laurylsulfate, talc, titanium dioxide, or combinations thereof.

Filler/binder weight fraction

The tablet wherein the pharmaceutical acceptable excipient includes a filler/binder present at about 20% to about 90% by weight of the tablet.

Lubricant weight fraction

The tablet wherein the pharmaceutical acceptable excipient includes at least one lubricant present at about 0% to about 5% by weight.

Bioequivalence acceptance ranges for mean AUC and mean Cmax

The tablet characterized by 90% confidence intervals showing the ratio of mean AUC(0-∞) and the ratio of mean Cmax, relative to a reference dasatinib monohydrate listed drug, both between 80% and 125%.

AUC(0-∞) exclusion criterion for acceptance interval determination

For oral administration of the tablet relative to a dasatinib monohydrate reference listed drug, the 90% confidence-interval acceptance ranges for the ratios of mean AUC(0-∞) and mean Cmax are determined by excluding subjects whose AUC(0-∞) is less than 5% of the reference listed drug.

Overall, the claim set centers on a tablet containing dasatinib (S)-1,2-propanediol solvate that meets a defined USP Type 2 rapid-release criterion, and it further specifies dependent refinements to excipient/coating components and to regulatory bioequivalence characterization using 90% confidence intervals for AUC(0-∞) and Cmax relative to a reference dasatinib monohydrate listed drug.

Stated Advantages

Improved dissolution/release, characterized by releasing at least 80% of dasatinib within 20 minutes under specified USP Type 2 conditions.

Regulatory bioequivalence characterization versus a dasatinib monohydrate reference listed drug using 90% confidence interval acceptance ranges for AUC(0-∞) and Cmax between 80% and 125%.

Comparable bioavailability versus Sprycel® (dasatinib monohydrate) as characterized in the example pharmacokinetic study.

Documented Applications

Rapid oral dasatinib solid dosage form as a tablet for oral administration.

Oral bioequivalence evaluation versus a reference dasatinib monohydrate listed drug (Sprycel®), including characterization using 90% confidence interval acceptance criteria.

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.